GPE
Hua Medicine Advances Dorzagliatin Expansion Beyond China with Hong Kong NDA Acceptance
Hua Medicine; dorzagliatin; diabetes drug; China expansion; Hong Kong NDA; Southeast Asia; glucokinase activator
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment
Alzheimer’s treatment; next-generation drugs; BIIB080; mivelsiran; trontinemab; remternetug
Novo Nordisk Foundation Commits Over $850M to Danish Life Science Incubator BII Over Next Decade
Novo Nordisk Foundation; BII; life science incubator; $850M; biotech startups; Denmark
JPM26 Day 3: Sanofi CEO on RSV Scrutiny and Regeneron Dupixent Defense
JPM26; Sanofi; RSV; Beyfortus; Paul Hudson; FDA; vaccines; Dupixent; Regeneron
Insilico Medicine Integrates Nach01 Foundation Model with Microsoft Discovery for AI-Native Drug Discovery
Insilico Medicine; Nach01; Microsoft Discovery; AI drug discovery; Azure; foundation model
JPM26: Novo Nordisk and Eli Lilly Compete Fiercely in Oral Obesity Treatments
Novo Nordisk; Eli Lilly; oral obesity drugs; JPM26; JPMHC; orglipron; semaglutide
Novartis Licenses Undisclosed Radioligand Therapy Asset from China’s Zonsen PepLib Biotech
Novartis; Zonsen PepLib; radiopharma; radioligand therapy; licensing deal; China biotech
JPM26 Live Blog Day 2: GSK Stays the Course Amid Key Biopharma Updates
JPM26; GSK; J.P. Morgan Healthcare Conference; Day 2; AstraZeneca; Novo Nordisk; biotech
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
Pfizer; Obesity Drugs; Metsera; Phase III Trials; Albert Bourla; JPM26; Patent Cliff
JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus
BMS; JPM26; early-stage bets; pipeline; Cobenfy; Milvexian; Admilparant; Pumitamig; Camzyos